80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]余煒,黃靜,余輝,等.基于介孔二氧化硅和聚多巴胺納米載體遞送阿帕替尼的性質(zhì)研究[J].福建醫(yī)藥雜志,2024,46(02):114-118.[doi:10.20148/j.fmj.2024.02.031]
　YU Wei,HUANG Jing,YU Hui,et al.Study on the properties of apatinib delivery based on mesoporous silica and polydopamine nanocarriers[J].FUJIAN MEDICAL JOURNAL,2024,46(02):114-118.[doi:10.20148/j.fmj.2024.02.031]
點(diǎn)擊復(fù)制

基于介孔二氧化硅和聚多巴胺納米載體遞送阿帕替尼的性質(zhì)研究()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期數(shù):
2024年02期
頁(yè)碼:
114-118
欄目:
基礎(chǔ)研究
出版日期:
2024-04-15

文章信息/Info

Title:
Study on the properties of apatinib delivery based on mesoporous silica and polydopamine nanocarriers
文章編號(hào):
1002-2600(2024)02-0114-05
作者:
余煒1; 黃靜1; 余輝1; 魏丞2; 范芳1; 林海燕1; 林劍揚(yáng)1; 翁金森3
1 福建醫(yī)科大學(xué)腫瘤臨床醫(yī)學(xué)院 福建省腫瘤醫(yī)院臨床藥學(xué)室,福州 350014; 2 胃腸外科,福州 350014; 3 重癥醫(yī)學(xué)科,福州 350014
Author(s):
YU Wei1; HUANG Jing1; YU Hui1; WEI Cheng2; FAN Fang1; LIN Haiyan1; LIN Jianyang1; WENG Jinsen3
1 Department of Clinical Pharmacy, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou, Fujian 350122, China; 2 Department of Gastrointestinal Surgery, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou, Fujian 350122, China; 3 Department of Critical Care Medicine, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou, Fujian 350122, China
關(guān)鍵詞:
抗腫瘤;  阿帕替尼;  MSNs@PDA-Apa;  納米粒子
Keywords:
antitumor;  apatinib;  MSNs@PDA-Apa;  nanoparticle
分類號(hào):
R943
DOI:
10.20148/j.fmj.2024.02.031
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討基于介孔二氧化硅和聚多巴胺的納米載體遞送阿帕替尼的效能。方法 利用介孔二氧化硅(MSN)的高效藥物遞送能力和聚多巴胺(PDA)的pH響應(yīng)性,采用改進(jìn)的Stober法制備了介孔二氧化硅納米粒子,根據(jù)靜電復(fù)合法設(shè)計(jì)了一種pH響應(yīng)性聚多巴胺(PDA)包覆的介孔二氧化硅納米給藥系統(tǒng)(MSNs@PDA)。采用掃描電子顯微鏡(SEM)和Zeta電位改變驗(yàn)證MSNs@PDA系統(tǒng)制備是否成功。測(cè)定MSNs@PDA-Apa的載藥量和包埋率。CCK-8法評(píng)價(jià)體外細(xì)胞毒性。Transwell法評(píng)價(jià)細(xì)胞遷移。結(jié)果 掃描電子顯微鏡(SEM)和Zeta電位改變驗(yàn)證MSNs@PDA-Apa制備成功。MSNs@PDA-Apa的藥物載藥量為2.4%,包埋率為48%±2.5%。MSNs@PDA-Apa組的細(xì)胞毒性呈濃度依賴性,當(dāng)濃度達(dá)到10 μg/mL時(shí),PC-9細(xì)胞的存活率僅為30%左右。與Apa組相比,MSNs@PDA-Apa組對(duì)細(xì)胞遷移的效果明顯增強(qiáng)。結(jié)論 MSNs@PDA-Apa具有較高的藥物傳遞效率,表現(xiàn)出對(duì)腫瘤細(xì)胞的良好殺傷作用,有望為未來(lái)的藥物傳遞系統(tǒng)的構(gòu)筑提供思路和方法。
Abstract:
Objective To explore the efficacy of nanocarriers based on mesoporous silica and polydopamine for delivering apatinib.Methods By utilizing the efficient drug delivery ability of mesoporous silica(MSN)and the pH responsiveness of polydopamine(PDA), mesoporous silica nanoparticles were prepared using an improved Stober method.A pH responsive polydopamine(PDA)coated mesoporous silica nanodrug delivery system was designed based on electrostatic composite method(MSNs@PDA).The success of MSNs@PDA system preparation was verified by scanning electron microscopy(SEM)and Zeta potential changes.The drug loading capacity and embedding rate of MSNs@PDA-Apa were determined.Vitro cytotoxicity was evaluated by the CCK-8 method.Transwell method was used to evaluate cell migration.Results MSNs@PDA system preparation was successful, which was verified by scanning electron microscopy(SEM)and Zeta potential changes.The drug loading capacity of MSNs@PDA-Apa was 2.4%, and the embedding rate was 48%±2.5%.The cytotoxicity of MSNs@PDA-Apa group was concentration dependent, and when the concentration reached 10 μg/mL, the survival rate of PC-9 cells was only about 30%.Compared to the Apa group, the effect of MSNs@PDA-Apa group on cell migration was significantly enhanced.Conclusion MSNs@PDA-Apa system preparation has a high drug delivery efficiency and exhibits a good killing effect on tumor cells, which is expected to provide ideas and methods for the construction of future drug delivery systems.

參考文獻(xiàn)/References:

[1] YANG Y Y,YU Y J,CHEN H,et al.Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-i/ii imaging and glutathione scavenging[J].ACS Nano,2020,14(10):13536-13547.
[2] ZHANG P H,GAO D,AN K L,et al.A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates[J].Chem,2020,12(4):381-390.
[3] ZHANG C,BU W B,NI D L,et al.Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction[J].Angew Chem Int Ed,2016,55(6):2101-2106.
[4] XIAO M S,LAI W,WANG F,et al.Programming drug delivery kinetics for active burst release with DNA toehold switches[J].Am Chem Soc,2019,141(51):20354-20364.
[5] DAI X M,MA J F,CHEN N N,et al.MSNs-based nanocomposite for biofilm imaging and NIR-activated chem/photothermal/photodynamic combination therapy[J].ACS Appl Bio Mater,2021,4(3):2810-2820.
[6] LIU X,YANG T,HAN Y,et al.In situ growth of cus/SiO2-based multifunctional nanotherapeutic agents for combined photodynamic/photothermal cancer therapy[J].ACS Appl Mater Interfaces,2018,10(37):31008-31018.
[7] KIM J W,JO C S,LIM W G,et al.Programmed nano-particleloaded nanoparticles for deep-penetrating 3D cancer therapy[J].Adv Mater,2018,30(29):e1707557.
[8] MÖLLER K,BEIN T.Talented mesoporous silica nanopar-ticles[J].Chem Mater,2017,29(1):371-388.
[9] ZHANG P H,CHENG F F,ZHOU R,et al.DNA-hybrid-gated multifunctional mesoporous silica nanocarriers for dual-targeted and microRNA-responsive controlled drug delivery[J].Angew Chem Int Ed,2014,53(9):2371-2375.
[10] HIRSCH F R,SCAGLIOTTI G V,MULSHINE J L,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311.
[11] LIU M,XU S,WANG Y,et al.PD 0332991,a selective cyclin D kinase 4/6 inhibitor,sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors[J].Oncotarget,2016,7(51):84951-84964.
[12] WUTTKE S,LISMONT M,ESCUDERO A,et al.Positioning metal-organic framework nanoparticles within the context of drug delivery—A comparison with mesoporous silica nanoparticles and dendrimers[J].Biomaterials,2017,123:172-183.

相似文獻(xiàn)/References:

[1]趙 珅 范南峰 李 惠 劉 捷 俞嘉青 林榕波.阿帕替尼聯(lián)合紫杉醇化療方案治療紫杉醇耐藥的晚期胃癌的臨床研究[J].福建醫(yī)藥雜志,2020,42(01):16.
　ZHAO Shen,FAN Nanfeng,LI Hui,et al.Clinical study of apatinib combined with paclitaxel chemotherapy in the treatment of paclitaxel-resistant advanced gastric cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(02):16.

備注/Memo

備注/Memo:
基金項(xiàng)目:福建省自然科學(xué)基金項(xiàng)目(2020J011119)
通信作者:翁金森,Email:[email protected]
更新日期/Last Update: 2024-04-15